ISBT 128 is the global standard for the terminology, identification, coding and labelling of medical products of human origin.  The ISBT 128 standard labelling of apheresis collection products for sponsor cellular therapy manufacturing was published in December 2020, however implementation has been low.  Capacity and infrastructure constraints at NHS sites have significantly contributed to this, with sites being unable to meet the ISBT 128 standard.  Newcastle upon Tyne Hospitals NHS Foundation Trust agreed to take part in the implementation of ISBT 128, in order for learnings and best practice to be disseminated to other sites across the UK.  The full report can be accessed here.